The role of dordaviprone in the multidisciplinary management of diffuse midline glioma
Abdullah M. Al Lawati, Mohammed K. Al Suleimani, Iman A. Al Rasbi, Mohammed A. Al Hinai, Sara B. Al Marbouai, Hoor B. Al Barhi, Hanan M. Al Lawati, Ghusn S. Al Sideiri · 2026
Read The role of dordaviprone in the multidisciplinary management of diffuse midline glioma by Abdullah M. Al Lawati, Mohammed K. Al Suleimani, Iman A. Al Rasbi, Mohammed A. Al Hinai, Sara B. Al Marbouai, Hoor B. Al Barhi, Hanan M. Al Lawati, Ghusn S. Al Sideiri (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13224274.txt.
Description
Abdullah Al Lawati and co-authors review in 2026 a drug called dordaviprone for a deadly brain tumor of children and young adults. The tumor, diffuse midline glioma, grows inside central brain structures where surgery cannot reach. Radiation is the only standard care and helps little. The drug crosses into the brain and attacks tumor cells two ways at once.
It switches on a protein-chopping enzyme and blocks a dopamine receptor, wrecking the tumor's energy system. Studies found durable responses in tumors with a key mutation, and side effects were mostly mild, like fatigue and nausea. The drug won accelerated approval in the United States in 2025. The authors place it inside team-based care.
Catalog record
| CREATOR | Abdullah M. Al Lawati, Mohammed K. Al Suleimani, Iman A. Al Rasbi, Mohammed A. Al Hinai, Sara B. Al Marbouai, Hoor B. Al Barhi, Hanan M. Al Lawati, Ghusn S. Al Sideiri |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |